Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action

Autor: Dd, Schoepp, Paul Ornstein, Jd, Leander, Lodge D, Cr, Salhoff, Zeman S, Dm, Zimmerman

Publikováno v: Europe PubMed Central

This study reports the activity of a structurally novel excitatory amino acid receptor antagonist, LY233053 [cis-(+-)-4-[(2H-tetrazol-5-yl)methyl]piperidine-2-carboxylic acid], the first tetrazole-containing competitive N-methyl-D-aspartic acid (NMDA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b33e91ad2447096f29828e2c07323de7
https://pubmed.ncbi.nlm.nih.gov/2148188

Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock, in rats and pigeons

Autor: CD Overshiner, Mark J. Benvenga, James A. Monn, JD Leander

Publikováno v: Behavioural Pharmacology. 8:642

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d84ceab9783b7ecc51cc0e8ec3b7313d
https://doi.org/10.1097/00008877-199711000-00027

Behavioral Effects of a Novel Benzofuranyl-Piperazine Serotonin-2C Receptor Agonist Suggest a Potential Therapeutic Application in the Treatment of Obsessive-Compulsive Disorder.

Autor: Rodriguez MM; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Overshiner C; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Leander JD; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Li X; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Morrow D; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Conway RG; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Nelson DL; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Briner K; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA., Witkin JM; Neuroscience Discovery Research and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA.

Publikováno v: Frontiers in psychiatry [Front Psychiatry] 2017 May 22; Vol. 8, pp. 89. Date of Electronic Publication: 2017 May 22 (Print Publication: 2017).

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects.

Autor: Burgdorf J; Department of Biomedical Engineering, Falk Center for Molecular Therapeutics, McCormick School of Engineering and Applied Sciences, Northwestern University, Evanston, IL 60201, USA., Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR

Publikováno v: Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2013 Apr; Vol. 38 (5), pp. 729-42. Date of Electronic Publication: 2012 Dec 05.

Comparison of the effects of antipsychotics on a delayed radial maze task in the rat.

Autor: Wolff MC; Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Mail Code No. 0510, Indianapolis, IN 46285, USA. wolff_mary_c@lilly.com, Leander JD

Publikováno v: Psychopharmacology [Psychopharmacology (Berl)] 2003 Aug; Vol. 168 (4), pp. 410-6. Date of Electronic Publication: 2003 Apr 23.